Your GLP-1 Purity Might Vary More Than You Think

The New FDA Stance on Compounding Pharmacies

The FDA recently made a major decision about how certain peptide drugs, like the GLP-1 agonists used in research, can be made. Their advisors voted to allow "compounders" to keep making versions of some of these compounds. This is big news for researchers who rely on these sources for their materials.

So, what is compounding? Think of a big drug company like a car factory. It builds thousands of identical cars on an assembly line. A compounding pharmacy is more like a custom auto shop. A doctor writes a specific recipe, and the pharmacist mixes that exact formulation for one patient. For researchers, this means access to compounds that might not be available from a single large-scale manufacturer.

The core issue is a drug shortage. When a major manufacturer can't make enough of a compound, the FDA can allow compounders to step in. The recent vote determined that the shortage of these specific GLP-1 agonists is real enough to justify this. For your research, this confirms that compounded sources will remain part of the supply chain.

What This Means for Your Research Samples

This decision puts more responsibility on you, the researcher. Compounding is a skilled process, but it's not the same as large-scale manufacturing. The final product's purity, sterility, and concentration can vary between different compounding pharmacies, and even between different batches from the same one.

Imagine you asked two different bakers to make you a vanilla cake from the same recipe. They might both be good, but one could be a bit sweeter, or one might use a slightly different type of vanilla. The cakes are fundamentally the same, but the details differ. With compounded peptides, you must verify the details for every new vial that enters your lab.

Your primary concern is sample integrity. A vial labeled "99% pure" from a compounding source needs scrutiny. What is the other 1%? Is it a harmless salt, or is it a fragment of the peptide chain from an incomplete synthesis? Is there bacterial endotoxin present? These are questions you must consider when planning experiments.

Your Bench Checklist for Compounded Samples

When a compounded peptide vial arrives at your bench, your process matters. These steps help protect your work from the start.

• Inspect the Vial: Before you even reconstitute, look at the lyophilized cake or powder. It should be uniform. Strange colors, oily droplets, or excessive clumping are red flags.
• Choose Your Diluent Wisely: For most peptides, bacteriostatic water is the standard choice. The "bacteriostatic" part means it contains a small amount of an agent like benzyl alcohol that prevents bacterial growth after you've added it. It's like adding a drop of lemon juice to a cut apple to keep it from browning. This is vital for multi-use vials.
• Reconstitute Gently: Add your diluent slowly down the side of the vial. Don't jab the needle into the powder cake. Swirl the vial gently until the powder is fully dissolved. Aggressive shaking can shear the delicate peptide chains, breaking them apart and ruining your sample's activity.
• Cold Storage is Non-Negotiable: Once reconstituted, most peptides degrade quickly at room temperature. Your working solution should go in the fridge (2-8°C) immediately. For long-term storage of the unused powder, the freezer (-20°C or colder) is standard. Temperature fluctuations are the enemy of peptide stability.
• Calculate Your Concentration with Care: This is a common source of error. If a vial says "5 mg" and you add 2 mL of bacteriostatic water, you have a 2.5 mg/mL solution. But where did you draw the liquid to in the syringe? Always account for the dead space in the needle. Precision here ensures your experimental results are based on accurate amounts.

The Bigger Picture: Purity and Source Verification

The FDA's move acknowledges a complex reality. These compounds are in high demand, and a single manufacturer cannot always meet it. For the research community, this means compounded sources are here to stay. Your best tool is diligence.

Ask your supplier for a Certificate of Analysis (CoA). This document should detail the purity of the peptide (often tested with HPLC, a method that separates and measures components in a mixture) and confirm it's free from bacteria. A CoA from an independent, third-party lab is more reliable than one from the manufacturer alone.

Think of it like buying a used car. You can either trust the seller's word, or you can take it to your own mechanic for an independent inspection. The CoA is your independent inspection report. If a supplier can't or won't provide one, that tells you everything you need to know about the quality of the material you're putting into your experiments. This vigilance ensures the data you generate is based on the compound you think you have.

Frequently asked questions

What should I look for on a Certificate of Analysis (CoA) for compounded peptides?

Check for purity percentage (from HPLC testing), confirmation of the correct peptide sequence, and tests for bacterial endotoxins and sterility. An independent lab's CoA is best.

How should I store reconstituted GLP-1 peptides from a compounding pharmacy?

Store the reconstituted solution in the refrigerator (2-8°C) immediately. For long-term storage of unused solution, aliquoting and freezing at -20°C or colder is recommended to avoid freeze-thaw cycles.

Does the FDA's decision on compounding affect the purity of the peptides I receive?

The decision allows compounding to continue but doesn't set purity standards. Purity varies by pharmacy. You must verify quality through inspection and by requesting independent Certificates of Analysis (CoAs).

Prompted by this coverage at Google News →

Related from our lab: the pen · cartridges · bacteriostatic water · reconstitution calculators

Shared by PreppinPeppers for research, educational, and demonstration awareness only. We link to third-party coverage; we do not endorse it, and nothing here is medical advice or a recommendation to use any substance in humans or animals. Our products are sold for laboratory research use only.

What the research community gets wrong about compounded GLP-1 peptides

Compounded GLP-1 agonists (peptides like semaglutide and tirzepatide) show up at the bench with a lot of assumptions attached to them. A few of those assumptions cause the most trouble when you are logging what is actually in the vial.

• A purity number is not the whole picture. A label that says "99% pure" tells you nothing about what the other 1% is, or how it was measured. Ask which method was used (usually HPLC) and whether the named impurities are salts, truncated fragments, or related peptides.
• A Certificate of Analysis is not automatically independent. Many CoAs are produced by the same source that sold the material. An analysis from a separate third-party lab is a different kind of check, and the two do not always agree.
• "Compounded" does not mean "reviewed like an approved product." The FDA-listed reference labels for these peptides went through review. Compounded material did not, so purity, sequence, and concentration can vary between suppliers and even between batches from one supplier.
• The same name does not mean the same molecule in the vial. These are long chains, so a different salt form, a shortened fragment, or a closely related peptide can carry the same name on paper and still behave differently in your assay.
• A clean CoA does not guarantee a clean working solution. A high-purity powder can still lose integrity from rough reconstitution, warm storage, or repeated freeze-thaw. What you verify on arrival is not what you have weeks later unless you handle and store it carefully.

From our bench: If you have run the same compounded GLP-1 peptide from two different suppliers or two different batches, we want the real numbers. Send us your measured HPLC purity readings, any named impurity peaks, and what your CoA source was (in-house versus third-party lab), and we will add anonymized, side-by-side observations here so other researchers can compare against real batch-to-batch data instead of guesses.

Sources

1. Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
2. Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
3. Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
4. PubChem, Semaglutide (CID 56843331), GLP-1 receptor agonist peptide record, NIH/NCBI
5. PubChem, Tirzepatide (CID 156588324), dual GLP-1/GIP receptor agonist peptide record, NIH/NCBI
6. DailyMed, FDA-approved semaglutide labels (Ozempic, Wegovy, Rybelsus), NIH/NLM